Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lefamulin - Nabriva Therapeutics

Next Previous
Drug Profile

Lefamulin - Nabriva Therapeutics

Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate; XENLETA

Latest Information Update: 07 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nabriva Therapeutics
  • Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bacterial infections; Bone and joint infections; Nosocomial pneumonia; Osteomyelitis
  • No development reported Sexually transmitted infections

Most Recent Events

  • 30 Dec 2019 Adverse events pooled data from two phase III trials in community acquired pneumonia presented at the IDWeek (IDWeek-2019)
  • 28 Nov 2019 No recent reports of development identified for preclinical development in Sexually transmitted infections in USA (IV, Infusion)
  • 28 Nov 2019 No recent reports of development identified for preclinical development in Sexually transmitted infections in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top